Logo image of VAPO

VAPOTHERM INC (VAPO) Stock Fundamental Analysis

NYSE:VAPO - New York Stock Exchange, Inc. - US9221073052 - Common Stock - Currency: USD

1.27  +0.08 (+6.72%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VAPO. VAPO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. VAPO may be in some trouble as it scores bad on both profitability and health. VAPO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

VAPO had negative earnings in the past year.
VAPO had a negative operating cash flow in the past year.
In the past 5 years VAPO always reported negative net income.
In the past 5 years VAPO always reported negative operating cash flow.
VAPO Yearly Net Income VS EBIT VS OCF VS FCFVAPO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

VAPO has a worse Return On Assets (-86.17%) than 79.70% of its industry peers.
Industry RankSector Rank
ROA -86.17%
ROE N/A
ROIC N/A
ROA(3y)-59.67%
ROA(5y)-53.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VAPO Yearly ROA, ROE, ROICVAPO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

The Gross Margin of VAPO (36.12%) is worse than 66.83% of its industry peers.
In the last couple of years the Gross Margin of VAPO has declined.
The Profit Margin and Operating Margin are not available for VAPO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 36.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.98%
VAPO Yearly Profit, Operating, Gross MarginsVAPO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

VAPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VAPO has more shares outstanding
Compared to 1 year ago, VAPO has a worse debt to assets ratio.
VAPO Yearly Shares OutstandingVAPO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M
VAPO Yearly Total Debt VS Total AssetsVAPO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -9.96, we must say that VAPO is in the distress zone and has some risk of bankruptcy.
VAPO has a Altman-Z score of -9.96. This is in the lower half of the industry: VAPO underperforms 76.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.96
ROIC/WACCN/A
WACC10.3%
VAPO Yearly LT Debt VS Equity VS FCFVAPO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

VAPO has a Current Ratio of 3.04. This indicates that VAPO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.04, VAPO is in line with its industry, outperforming 44.55% of the companies in the same industry.
VAPO has a Quick Ratio of 1.61. This is a normal value and indicates that VAPO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.61, VAPO is doing worse than 66.83% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 1.61
VAPO Yearly Current Assets VS Current LiabilitesVAPO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

VAPO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.56%, which is quite impressive.
The Revenue has decreased by -3.95% in the past year.
VAPO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.41% yearly.
EPS 1Y (TTM)34.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.64%
Revenue 1Y (TTM)-3.95%
Revenue growth 3Y11.57%
Revenue growth 5Y13.41%
Sales Q2Q%11.96%

3.2 Future

The Earnings Per Share is expected to grow by 18.76% on average over the next years. This is quite good.
Based on estimates for the next years, VAPO will show a quite strong growth in Revenue. The Revenue will grow by 18.62% on average per year.
EPS Next Y81.61%
EPS Next 2Y35.65%
EPS Next 3Y23.77%
EPS Next 5Y18.76%
Revenue Next Year5.53%
Revenue Next 2Y10.65%
Revenue Next 3Y11.78%
Revenue Next 5Y18.62%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VAPO Yearly Revenue VS EstimatesVAPO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
VAPO Yearly EPS VS EstimatesVAPO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VAPO. In the last year negative earnings were reported.
Also next year VAPO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VAPO Price Earnings VS Forward Price EarningsVAPO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VAPO Per share dataVAPO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

A more expensive valuation may be justified as VAPO's earnings are expected to grow with 23.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.65%
EPS Next 3Y23.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VAPO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAPOTHERM INC

NYSE:VAPO (12/14/2023, 8:19:45 PM)

1.27

+0.08 (+6.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-08 2023-11-08/amc
Earnings (Next)02-21 2024-02-21/amc
Inst Owners0.01%
Inst Owner Change-99.24%
Ins Owners75.19%
Ins Owner Change0%
Market Cap7.80M
Analysts45
Price Target1.02 (-19.69%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.52%
Min EPS beat(2)-12.72%
Max EPS beat(2)15.76%
EPS beat(4)2
Avg EPS beat(4)0.97%
Min EPS beat(4)-12.72%
Max EPS beat(4)15.76%
EPS beat(8)2
Avg EPS beat(8)-8.77%
EPS beat(12)3
Avg EPS beat(12)-7.3%
EPS beat(16)6
Avg EPS beat(16)-4.39%
Revenue beat(2)0
Avg Revenue beat(2)-7.5%
Min Revenue beat(2)-7.51%
Max Revenue beat(2)-7.49%
Revenue beat(4)1
Avg Revenue beat(4)-4.45%
Min Revenue beat(4)-7.51%
Max Revenue beat(4)2.47%
Revenue beat(8)2
Avg Revenue beat(8)-5.96%
Revenue beat(12)5
Avg Revenue beat(12)-0.69%
Revenue beat(16)8
Avg Revenue beat(16)1.3%
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.91%
EPS NY rev (1m)41.78%
EPS NY rev (3m)41.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)97866.5%
Revenue NY rev (1m)-1.89%
Revenue NY rev (3m)-1.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-14.54
EYN/A
EPS(NY)-4.44
Fwd EYN/A
FCF(TTM)-5.95
FCFYN/A
OCF(TTM)-5.09
OCFYN/A
SpS11.01
BVpS-7.74
TBVpS-7.82
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 36.12%
FCFM N/A
ROA(3y)-59.67%
ROA(5y)-53.68%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-14.95%
GM growth 5Y-5.98%
F-Score4
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 109.05%
Cap/Sales 7.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 1.61
Altman-Z -9.96
F-Score4
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)178%
Cap/Depr(5y)185.39%
Cap/Sales(3y)10.13%
Cap/Sales(5y)10.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.64%
EPS Next Y81.61%
EPS Next 2Y35.65%
EPS Next 3Y23.77%
EPS Next 5Y18.76%
Revenue 1Y (TTM)-3.95%
Revenue growth 3Y11.57%
Revenue growth 5Y13.41%
Sales Q2Q%11.96%
Revenue Next Year5.53%
Revenue Next 2Y10.65%
Revenue Next 3Y11.78%
Revenue Next 5Y18.62%
EBIT growth 1Y35.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.89%
EBIT Next 3Y24.47%
EBIT Next 5YN/A
FCF growth 1Y33.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.93%
OCF growth 3YN/A
OCF growth 5YN/A